Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral H. pylori and Gastric Eradication Efficacy
NCT05790525Phase 4Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial in Helicobacter pylori infection (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Eradication rate of Helicobacter pylori in the stomach. Started Nov 2022; status: completed.
02
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05790525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790525.